mRNA COVID-19 Vaccine Favorable Among Patients With Myasthenia Gravis
Researchers sought to assess whether the mRNA-1273 vaccine is safe and induces humoral and cellular responses in patients with MG.
Researchers sought to assess whether the mRNA-1273 vaccine is safe and induces humoral and cellular responses in patients with MG.
In a cross-sectional study, researchers investigated MG-related and generic factors associated with PASS status among patients with gMG to assess their satisfaction with symptoms.
Researchers sought to present results from the European LEMS registry on safety data and long-term outcomes for patients with LEMS being treated with 3,4-DAP and 3,4-DAPP.
The approval was based on data from a phase 3 study that included 175 adults with generalized myasthenia gravis who were not previously treated with a complement inhibitor.
Researchers reported results from an interim analysis of an ongoing open-label extension to study the safety and efficacy of adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis.
In a retrospective study, researchers investigated the autoantibody profile and clinical characteristics of patients with refractory myasthenia gravis, compared to patients nonrefractory status, based on predefined criteria.
In a retrospective, observational study, researchers determined the impact of COVID-19 infection in patients with myasthenia gravis.
Researchers sought to determine the clinical, immunologic, and therapeutic characteristics in patients with drug-refractory myasthenia gravis and to determine the effectiveness and side effects of drugs used for treatment.
Researchers sought to assess the outcomes of invasive ventilation, mortality, and hospital length of stay among patients presenting with myasthenia gravis and COVID-19.
In a retrospective study, researchers analyzed the potential association between anti-acetylcholine receptor antibody serum levels and the clinical improvement of myasthenia gravis.